eFFECTOR Therapeutics, Inc.

NasdaqCM:EFTR Stock Report

Market Cap: US$6.7m

eFFECTOR Therapeutics Management

Management criteria checks 2/4

eFFECTOR Therapeutics' CEO is Steve Worland, appointed in May 2012, has a tenure of 11.92 years. total yearly compensation is $1.22M, comprised of 48.8% salary and 51.2% bonuses, including company stock and options. directly owns 0.9% of the company’s shares, worth $60.06K. The average tenure of the management team and the board of directors is 3.3 years and 2.7 years respectively.

Key information

Steve Worland

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage48.8%
CEO tenure11.9yrs
CEO ownership0.9%
Management average tenure3.3yrs
Board average tenure2.7yrs

Recent management updates

Recent updates

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

Sep 14

eFFECTOR Therapeutics GAAP EPS of -$0.17

Aug 09

eFFECTOR: Developing New Class Of Cancer Therapies

Sep 12

CEO Compensation Analysis

How has Steve Worland's remuneration changed compared to eFFECTOR Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$1mUS$595k

-US$36m

Sep 30 2023n/an/a

-US$36m

Jun 30 2023n/an/a

-US$37m

Mar 31 2023n/an/a

-US$36m

Dec 31 2022US$4mUS$567k

-US$23m

Sep 30 2022n/an/a

US$6m

Jun 30 2022n/an/a

US$24m

Mar 31 2022n/an/a

US$25m

Dec 31 2021US$3mUS$501k

US$16m

Sep 30 2021n/an/a

-US$4m

Jun 30 2021n/an/a

-US$20m

Mar 31 2021n/an/a

-US$7m

Dec 31 2020US$645kUS$452k

US$166k

Compensation vs Market: Steve's total compensation ($USD1.22M) is above average for companies of similar size in the US market ($USD668.06K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.


CEO

Steve Worland (65 yo)

11.9yrs

Tenure

US$1,217,505

Compensation

Dr. Stephen T. Worland, Ph D., also known as Steve, serves as Director at Blacksmith Medicines, Inc. He has been President and Chief Executive Officer of eFFECTOR Therapeutics, Inc. since May 2012 and has...


Leadership Team

NamePositionTenureCompensationOwnership
Stephen Worland
CEO, President & Director11.9yrsUS$1.22m0.90%
$ 60.1k
Michael Byrnes
Chief Financial Officer3.3yrsUS$826.59k0.047%
$ 3.1k
Douglas Warner
Chief Medical Officer1.7yrsUS$746.04k0%
$ 0
Davide Ruggero
Co-Founder and Member of Clinical & Scientific Advisory Boardno datano datano data
Kevan Shokat
Co-Founder and Member of Clinical & Scientific Advisory Boardno datano datano data

3.3yrs

Average Tenure

51yo

Average Age

Experienced Management: EFTR's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stephen Worland
CEO, President & Director2.7yrsUS$1.22m0.90%
$ 60.1k
Davide Ruggero
Co-Founder and Member of Clinical & Scientific Advisory Boardno datano datano data
Kevan Shokat
Co-Founder and Member of Clinical & Scientific Advisory Boardno datano datano data
Christopher Ehrlich
Independent Director2.7yrsUS$80.86k0.19%
$ 12.9k
Neal Rosen
Member of Clinical & Scientific Advisory Boardno datano datano data
Caroline Loewy
Independent Directorless than a yearUS$35.70k0.0098%
$ 653.4
Joan Brugge
Member of Clinical & Scientific Advisory Boardno datano datano data
Jennifer Doudna
Member of Clinical & Scientific Advisory Boardno datano datano data
Kapil Dhingra
Member of Clinical & Scientific Advisory Boardno datano datano data
Brian Gallagher
Independent Chairman4.3yrsUS$109.82k0.033%
$ 2.2k
Elizabeth Bhatt
Independent Director3.3yrsUS$74.58k0.0098%
$ 653.4
Funda Meric-Bernstam
Member of Clinical & Scientific Advisory Boardno datano datano data

2.7yrs

Average Tenure

57.5yo

Average Age

Experienced Board: EFTR's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.